Poseida Therapeutics’ (PSTX) “Buy” Rating Reiterated at HC Wainwright

Poseida Therapeutics (NASDAQ:PSTX)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report issued on Thursday, Benzinga reports. They currently have a $20.00 price target on the stock.

Poseida Therapeutics Trading Up 2.2 %

PSTX stock traded up $0.06 during trading on Thursday, hitting $2.83. The company had a trading volume of 833,059 shares, compared to its average volume of 716,364. The company has a quick ratio of 3.18, a current ratio of 3.18 and a debt-to-equity ratio of 0.56. The firm has a 50-day moving average price of $2.97 and a 200-day moving average price of $2.94. Poseida Therapeutics has a 12 month low of $1.54 and a 12 month high of $4.27. The stock has a market cap of $274.31 million, a price-to-earnings ratio of -2.04 and a beta of 0.46.

Poseida Therapeutics (NASDAQ:PSTX) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.09. Poseida Therapeutics had a negative net margin of 190.76% and a negative return on equity of 94.90%. The company had revenue of $25.00 million for the quarter, compared to the consensus estimate of $12.50 million. As a group, analysts predict that Poseida Therapeutics will post -1.77 earnings per share for the current year.

Hedge Funds Weigh In On Poseida Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in PSTX. Silverarc Capital Management LLC grew its holdings in Poseida Therapeutics by 21.1% during the third quarter. Silverarc Capital Management LLC now owns 3,567,985 shares of the company’s stock worth $8,492,000 after purchasing an additional 622,037 shares during the period. Blair William & Co. IL lifted its holdings in shares of Poseida Therapeutics by 30.2% during the third quarter. Blair William & Co. IL now owns 740,650 shares of the company’s stock worth $1,763,000 after buying an additional 171,910 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Poseida Therapeutics by 186.7% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 342,857 shares of the company’s stock valued at $816,000 after acquiring an additional 223,280 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Poseida Therapeutics by 10.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 259,929 shares of the company’s stock valued at $619,000 after acquiring an additional 23,960 shares during the period. Finally, MCF Advisors LLC boosted its position in shares of Poseida Therapeutics by 476.4% in the fourth quarter. MCF Advisors LLC now owns 247,024 shares of the company’s stock valued at $830,000 after acquiring an additional 204,170 shares during the period. 46.87% of the stock is owned by institutional investors.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.